Effect of Tadalafil Administration on Vasodilatation Mediated by Flow in Patients With Obesity Grade I-II

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

Obesity is a public health problem, not only for its high prevalence, but also because of the comorbidities found in it. Within the physiopathological mechanisms associated with obesity is a low-grade inflammatory state that is associated with endothelial dysfunction Endothelial dysfunction is known to be the beginning of the atherosclerotic process that eventually leads to the development of cardiovascular disease.

Erectile dysfunction is an example of endothelial dysfunction, where blood flow is compromised as a consequence of a reduction in the production of nitric oxide among others.

Tadalafil, which is an inhibitor of PDE-5, is currently used as a treatment for erectile dysfunction. However, it has been observed that the administration of tadalafil in patients with éndothelial dysfunction decreases arterial stiffness, having a positive effect on it, in addition it reduces the pulse pressure, systolic and diastolic pressure.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centro Universitario de Ciencias de la Salud, Mexico
• Treatments: Tadalafil

Criteria

Inclusion Criteria:

• Male patients

• Age 25 to 60 years

• Obesity grade I-II

• .Sign the inform consent form.

• Answer the questionary IIFE

Exclusion Criteria:

. DM 1-2

• Systemic arterial hypertension

• Uncontrolled Mixed Dyslipidemia or under Hypolipemiant Treatment with statins.

• Active smoking

• Precedent of uncontrolled Ischemic cardiopathy.

• Use of anti-inflammatory drugs, including Acetylsalicylic acid, antihypertensive, antihyperglucemic, anti-anginal drugs, recent use of antiviral drugs that contains vasoconstrictors.

• Hepatic, renal, thyroid, and/or pulmonary decompensated disease.

• The precedent of hypersensibility to the phosphodiesterase-5 inhibitors.

• Patients that are under treatmen with iPDE